SimpleSense vs Regard

A documentation or revenue-cycle team at a hospital is Regard's buyer. The vendor says it reads 100% of the chart and that every condition identified comes with an evidence chain, and that no diagnostic logic reaches patients without physician approval. Its solutions include HCC capture and a mid-revenue-cycle product for missed diagnoses before denials. The ONC certification, for "Regard SaaS Solution v.1" under 2015 Cures Update criteria, is dated May 2, 2024.

Nanowear's blood pressure product rests on a prospective 303-subject, four-week study by Nanowear authors with internal validation only, and the authors ask for external validation. Funding figures for the Brooklyn company conflict. Tracxn lists USD 1.52M over two rounds, ZoomInfo says under USD 5M over two rounds, and MobiHealthNews reported USD 1.5M in September 2014. A heart failure or cardiology clinic wanting patients in a sensor garment at home is Nanowear's buyer, which leaves no purchaser common to both tools.